HomeAbout UsContact Us1-800-477-6037
BioWorld MedTech
Archive Search

User ID

Password

Forgot password

Remember my login



New User ?

Products & Services
Medical Device Daily
Medtech Resources
BioWorld Executive Compensation Report 2014
MDD State of the Industry Report 2013
BioWorld and Medical Device VC Directory 2012
BioWorld Today
Biotech Resources
Perspectives Blog
PMA and 501(k) Approvals

Clarivate Analytics


Today's Issue of BioWorld MedTech

Tuesday, June 27, 2017

Today's Headlines

FDA approves the first companion Dx for use with multiple NSCLC drugs

The U.S. Food and Drug Administration has approved the Oncomine Dx Target Test from Thermo Fisher Scientific Inc. It is the first test of its kind to screen tumor samples for biomarkers associated with multiple cancer therapies, in this case for non-small-cell lung cancer (NSCLC). It is expected to enable more rapid evaluation of treatment options for these patients, in days rather than over several weeks.

Shares of med-tech firms surge as investors warm to sector, driven by optimism

Like their biopharmaceutical colleagues, publicly listed medical technology companies have roared out of the gate this year as investors flood back into health care. Companies have benefited from record-breaking market highs being driven by a increased optimism that the U.S. economy is poised to enjoy better times ahead.

Device deals climb with a focus on cancer, cardiovascular markets

The number of medical device deals and their disclosed values appear to be rising, according to data from Cortellis Deals Intelligence (CDI). CDI reported 202 med-tech deals in 2014, compared with 237 deals in 2015 and 287 deals in 2016. The total value of deals was $22.85 million in 2014, $251.06 million in 2015 and $1.54 billion in 2016.


MDD Home   |   About MDD   |   Contact Us   |   Copyright Notices   |   Terms of Use   |   Privacy Statement

clarivate.com | BioWorld.com | bioworldmedtech.com